ALKEMAlkem Laboratories Ltd.

₹5451-0.06%

Market Cap

₹65,195.21 Cr

Stock P/E

28.54

ROCE

21.56%

ROE

19.93%

Book Value

₹1055.25

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Solid FY25 performance with revenue and margin expansion.
•
Market leadership and outperformance across key metrics (volume, export growth, and prescription share).

NEGATIVES

•
Q4 gross margin pressure due to mix, inventory effects, Nimodipine settlement, and higher expiry effects.
•
US launch timing uncertainty for Entresto due to ongoing litigation.

Peers Summary

Sector Leader

Alkem Laboratories Ltd. stands out in the pharmaceuticals sector with impressive profitability metrics and solid growth, making it a strong competitor among its peers. Despite a moderate valuation, it remains a compelling choice for investors seeking stability and growth.

Key Points

• Alkem has a strong ROE of 19.93% and healthy profit margins, indicating solid profitability.
• Its PEG ratio of 0.17 suggests it is undervalued relative to its growth, making it an attractive investment.
• Compared to peers, Alkem's low debt-equity ratio (0.0889) suggests a conservative capital structure.

Top Performers

Mankind Pharma Ltd.

Highest revenue growth (YoY at 18.12%) and strong profitability with an ROE of 23.15%.

Dr. Reddy's Laboratories Ltd.

Best overall profitability with the highest ROA (16.08%) and low PE ratio (15.50), indicating strong value.

Cipla Ltd.

Consistent growth with a revenue YoY of 13.28% and attractive PEG ratio of 0.35.

Explore

Watchlists

Command Palette